ArticleJAC-antimicrobial resistance2022
Article in JAC-antimicrobial resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Contrasting In Vitro Activity of Nitroxoline Against Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- MappingAntibiotics (Basel, Switzerland) · 2026Article
- In Vitro and In Vivo Evaluation of Nitroxoline as an Effective Antimicrobial Alternative to Poultry Production.Antibiotics (Basel, Switzerland) · 2026Article
- [Prophylaxis of recurrent urinary tract infections by nitroxoline-real-world data of the ProNitrox study].Urologie (Heidelberg, Germany) · 2026Article
- Nitroxoline as an antimicrobial synergist reverses colistin resistance in multidrug-resistantiScience · 2025Article
- Urinary tract infection in outpatients in Germany: a cross-sectional study of diagnostics and susceptibility testing in medical laboratories.BJGP open · 2025Article
- In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species.Mycoses · 2025Article
- New Perspectives on Antimicrobial Agents: Pivmecillinam.Antimicrobial agents and chemotherapy · 2025Review
- Mecillinam activity against multidrug-resistantMicrobiology spectrum · 2025Article
- Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens.Open forum infectious diseases · 2024Review
- Nitroxoline resistance is associated with significant fitness loss and diminishesMicrobiology spectrum · 2024Article
- Nitroxoline: treatment and prevention of urinary tract infections from the urologist's perspective.Central European journal of urology · 2024Review
- Antimicrobial resistance of clinical Enterobacterales isolates from urine samples, Germany, 2016 to 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With increasing resistance to common antibiotics the treatment of urinary tract infections has become challenging and alternative therapeutic options are needed. In the present study, we evaluate the activity of three older and less frequently used antibiotics against MDR Enterobacterales. Methods: Susceptibility of mecillinam, temocillin and nitroxoline was assessed in Enterobacterales isolated from urinary specimens with elevated MICs of third-generation cephalosporins. Susceptibility was determined by the recommended reference MIC methods and additionally by disc diffusion. All isolates were characterized for common β-lactamases by phenotypic and molecular assays. Results: In total 394 Enterobacterales were included. The most common resistance mechanisms were ESBLs ( Conclusions: Mecillinam, temocillin and nitroxoline show good to excellent
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.